Zimbabwe has rejected a substantial US health deal worth $367m (£272m) over five years over Washington's request for sensitive data.
This rejection was revealed after a government memo from December was disclosed, which showed President Emmerson Mnangagwa believed the agreement was "lopsided".
An official spokesperson has since clarified that the US was requesting genetic material for research and profit while refused to share the benefits from any future vaccines.
"We are forced to start the difficult and regrettable task of winding down our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had furnished more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged more talks to find a deal acceptable to all parties so the country's critical HIV treatment initiative can be sustained.
Broader Implications
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a court suspended a similar deal with the US after legal challenges were raised about the security of citizens' medical information.
Since resuming office recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump claimed its expenditure was "inefficient" and his administration was seeking government-to-government agreements to enhance openness and accountability.
As per reports, Sixteen nations in Africa have to date agreed to similar agreements, constituting over $18.3bn in committed funds.
Details of the Rejected Agreement
The money for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation could have provided immense benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment via American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, with no corresponding promise of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that provided information," he stated.
"Effectively, our nation would provide the basic resources for scientific discovery without any assurance that the final treatments would be available to our people if a new disease outbreak arise."
Sovereignty and Global Health
He also pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were upending systems previously set up through the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system created to manage future pandemics.
"This system is intended to guarantee that when a nation provides its samples, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the capability to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how subsequent collaboration could be structured in a manner that respects the sovereignty and interests of each country."
Medical Community Reaction
Medical experts said it recognised the official position, but suggested that negotiations should continue considering much of the nation's HIV programmes depended on foreign aid.
"Where technical issues arise, including those relating to data governance or implementation frameworks, these can often be addressed via detailed discussion and negotiated safeguards," it added.
The situation highlights the ongoing tensions between accepting much-needed foreign assistance and safeguarding national sovereignty in an ever more data-driven world.